**§4.115b Ratings of the genitourinary system---diagnoses.**

Note: When evaluating any claim involving loss or loss of use of one or
more creative organs, refer to §3.350 of this chapter to determine
whether the veteran may be entitled to special monthly compensation.
Footnotes in the schedule indicate conditions which potentially
establish entitlement to special monthly compensation; however, there
are other conditions in this section which under certain circumstances
also establish entitlement to special monthly compensation.

Rating

**7500** Kidney, removal of one:

Minimum evaluation 30

Or rate as renal dysfunction if there is nephritis, infection,

or pathology of the other.

**7501** Kidney, abscess of:

Rate as urinary tract infection

**7502** Nephritis, chronic:

Rate as renal dysfunction.

**7504** Pyelonephritis, chronic:

Rate as renal dysfunction or urinary tract infection, whichever is

predominant.

**7505** Kidney, tuberculosis of:

Rate in accordance with §§4.88b or 4.89, whichever is appropriate.

**7507** Nephrosclerosis, arteriolar:

Rate according to predominant symptoms as renal dysfunction,

hypertension or heart disease. If rated under the cardiovascular

schedule, however, the percentage rating which would otherwise

be assigned will be elevated to the next higher evaluation.

**7508** Nephrolithiasis:

Rate as hydronephrosis, *except for* recurrent stone formation requiring
one or more of the following:

1\. diet therapy

2\. drug therapy

3\. invasive or non-invasive procedures more than two times/year 30

**7509** Hydronephrosis:

Severe; Rate as renal dysfunction.

Frequent attacks of colic with infection (pyonephrosis), kidney

function impaired 30

**7509** Hydronephrosis (cont.):

Frequent attacks of colic, requiring catheter drainage 20

Only an occasional attack of colic, not infected and not requiring

catheter drainage 10

**7510** Ureterolithiasis:

Rate as hydronephrosis, *except for* recurrent stone formation requiring
one or more of the following:

1\. diet therapy

2\. drug therapy

3\. invasive or non-invasive procedures more than two times/year 30

**7511** Ureter, stricture of:

Rate as hydronephrosis, *except for* recurrent stone formation requiring
one or more of the following:

1\. diet therapy

2\. drug therapy

3\. invasive or non-invasive procedures more than two times/year 30

**7512** Cystitis, chronic, includes interstitial and all etiologies,
infectious and non- infectious:

Rate as voiding dysfunction.

**7515** Bladder, calculus in, with symptoms interfering with function:

Rate as voiding dysfunction.

**7516** Bladder, fistula of:

Rate as voiding dysfunction or urinary tract infection, whichever is

predominant.

Postoperative, superapubic cystotomy 100

**7517** Bladder, injury of:

Rate as voiding dysfunction.

**7518** Urethra, stricture of:

Rate as voiding dysfunction.

**7519** Urethra, fistula of:

Rate as voiding dysfunction.

Multiple urethroperineal fistulae 100

**7520** Penis, removal of half or more 30

Or rate as voiding dysfunction.

**7521** Penis, removal of glans 20

Or rate as voiding dysfunction.

**7522** Penis, deformity, with loss of erectile power 201

**7523** Testis, atrophy complete:

Both 201

One 01

**7524** Testis, removal:

Both 301

One 01

1Review for entitlement to special monthly compensation under §3.350 of
this chapter.

Note: In cases of the removal of one testis as the result of a
service-incurred injury or disease, other than an undescended or
congenitally undeveloped testis, with the absence or nonfunctioning of
the other testis unrelated to service, an evaluation of 30 percent will
be assigned for the service-connected testicular loss. Testis,
undescended, or congenitally undeveloped is not a ratable disability.

**7525** Epididymo-orchitis, chronic only:

Rate as urinary tract infection.

For tubercular infections: Rate in accordance with §§4.88b or 4.89,

whichever is appropriate.

**7527** Prostate gland injuries, infections, hypertrophy,
post-operative residuals:

Rate as voiding dysfunction or urinary tract infection, whichever is

predominant.

**7528** Malignant neoplasms of the genitourinary system 100

Note: Following the cessation of surgical, X-ray, antineoplastic
chemotherapy or other therapeutic procedure, the rating of 100 percent
shall continue with a mandatory VA examination at the expiration of six
months. Any change in evaluation based upon that or any subsequent
examination shall be subject to the provisions of §3.105(e) of this
chapter. If there has been no local recurrence or metastasis, rate on
residuals as voiding dysfunction or renal dysfunction, whichever is
predominant.

**7529** Benign neoplasms of the genitourinary system:

Rate as voiding dysfunction or renal dysfunction, whichever is
predominant.

**7530** Chronic renal disease requiring regular dialysis:

Rate as renal dysfunction.

**7531** Kidney transplant:

Following transplant surgery 100

Thereafter: Rate on residuals as renal dysfunction, minimum rating 30

Note: The 100 percent evaluation shall be assigned as of the date of
hospital admission for transplant surgery and shall continue with a
mandatory VA examination one year following hospital discharge. Any
change in evaluation based upon that or any subsequent examination shall
be subject to the provisions of §3.105(e) of this chapter.

**7532** Renal tubular disorders (such as renal glycosurias,
aminoacidurias, renal

tubular acidosis, Fanconi's syndrome, Bartter's syndrome, related

disorders of Henle's loop and proximal or distal nephron function,
etc.):

Minimum rating for symptomatic condition 20

Or rate as renal dysfunction.

**7533** Cystic diseases of the kidneys (polycystic disease, uremic
medullary

cystic disease, Medullary sponge kidney, and similar conditions):

Rate as renal dysfunction.

**7534** Atherosclerotic renal disease (renal artery stenosis or
atheroembolic renal

disease):

Rate as renal dysfunction.

**7535** Toxic nephropathy (antibotics, radiocontrast agents,
nonsteroidal

anti-inflammatory agents, heavy metals, and similar agents):

Rate as renal dysfunction.

**7536** Glomerulonephritis:

Rate as renal dysfunction.

**7537** Interstitial nephritis:

Rate as renal dysfunction.

**7538** Papillary necrosis:

Rate as renal dysfunction.

**7539** Renal amyloid disease:

Rate as renal dysfunction.

**7540** Disseminated intravascular coagulation with renal cortical
necrosis:

Rate as renal dysfunction.

**7541** Renal involvement in diabetes mellitus, sickle cell anemia,
systemic

lupus erythematosus, vasculitis, or other systemic disease processes:

Rate as renal dysfunction.

**7542** Neurogenic bladder:

Rate as voiding dysfunction.

\[29 FR 6718, May 22, 1964, as amended at 34 FR 5063, Mar. 11, 1969; 40
FR 42540, Sept. 15, 1975; 41 FR 11301, Mar. 18, 1976; 41 FR 34258, Aug.
13, 1976; 59 FR 2527, Jan. 18, 1994; 59 FR 14567, Mar. 29, 1994; 59 FR
46339, Sept. 8, 1994\]

**Supplement *Highlights* references**: 7(1), 10(1).

*Next Section is §4.116*